{"product_id":"annexonbio-five-forces-analysis","title":"Annexon Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAnnexon faces concentrated supplier and buyer dynamics, emerging biotech entrants, and evolving substitute therapies that together shape its competitive runway; our concise snapshot highlights key pressure points and strategic levers. Unlock the full Porter's Five Forces Analysis to explore force-by-force ratings, visual summaries, and actionable recommendations tailored to Annexon’s market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Contract Development and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnnexon depends on a small set of specialized CDMOs for complex monoclonal antibodies like ANX005 and ANX007; by 2025 commercial scale needs could push annual CMO spend \u0026gt;$50M, and only ~10–15 global CDMOs have the required biologics capacity, giving suppliers strong pricing and scheduling leverage that can raise COGS and delay launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations and Trial Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnnexon’s ability to run global neurodegenerative and autoimmune trials hinges on specialized clinical research organizations (CROs) and sites; in 2024 CROs handled ~60% of late‑stage CNS trials, giving them leverage because mid‑study switches raise costs by 15–30% and can delay readouts 6–18 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers of Proprietary Biological Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe production of C1q inhibitors depends on proprietary cell lines and specialty media, some of which are covered by third-party patents; single-supplier control of key reagents could force Annexon to accept price hikes or shipment limits that raise COGS and delay 2025 milestones.\u003c\/p\u003e\n\u003cp\u003eIn 2024 the biologics supply shortage pushed reagent prices up ~12% in bioprocessing and caused lead-time extensions to 16–20 weeks, so Annexon should diversify vendors or secure multi-year agreements to protect timelines and budget.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific and Regulatory Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe global shortage of complement biology and neuro-immunology experts sharply raises suppliers' bargaining power; industry reports show demand for such specialists grew ~22% from 2019–2024 while supply lagged, driving salaries up 15–30% by 2024.\u003c\/p\u003e\n\u003cp\u003eAnnexon’s value depends on this scarce intellectual capital, so losing senior scientists or regulatory consultants to Big Pharma could delay programs by 6–18 months and cut peak revenue forecasts for C1q assets by tens of millions annually.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\n\u003cli\u003eDemand up ~22% (2019–2024)\u003c\/li\u003e\n\u003cli\u003eSalaries +15–30% (by 2024)\u003c\/li\u003e\n\u003cli\u003eTurnover delays: 6–18 months\u003c\/li\u003e\n\u003cli\u003eRevenue risk: tens of millions\/year\u003c\/li\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProviders of Specialized Laboratory Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced research into the classical complement pathway needs high-end imaging and analytics made by a few global firms; in 2024 the top five vendors held about 65% of the market for advanced lab imaging, reinforcing supplier concentration.\u003c\/p\u003e\n\u003cp\u003eThese suppliers enforce power via high switching costs, recurring software\/hardware maintenance (often 15–25% of initial equipment cost annually), and long validation cycles, leaving Annexon little room to negotiate.\u003c\/p\u003e\n\u003cp\u003eAnnexon accepts prevailing pricing to stay clinically competitive; for example, a single confocal\/EM system can cost $500k–$2M plus $75k–$400k\/year maintenance, constraining R\u0026amp;D budget flexibility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupplier concentration: top 5 = ~65% (2024)\u003c\/li\u003e\n\u003cli\u003eSwitching\/validation: months–years, high operational risk\u003c\/li\u003e\n\u003cli\u003eAnnual maintenance: 15–25% of capex ($75k–$400k)\u003c\/li\u003e\n\u003cli\u003eEquipment capex: $500k–$2M per system\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier dominance threatens Annexon: concentrated CDMO capacity, high costs, long lead times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong leverage over Annexon due to concentrated CDMO\/CRO capacity, patented reagents, scarce complement experts, and costly specialized equipment; risks: \u0026gt;$50M annual CMO spend by 2025, 10–15 qualified CDMOs, reagent lead times 16–20 weeks, salaries +15–30% (2019–24), top‑5 imaging vendors = ~65% market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected CMO spend (2025)\u003c\/td\u003e\n\u003ctd\u003e$50M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified CDMOs\u003c\/td\u003e\n\u003ctd\u003e10–15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent lead time (2024)\u003c\/td\u003e\n\u003ctd\u003e16–20 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSalary increase (2019–24)\u003c\/td\u003e\n\u003ctd\u003e+15–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑5 imaging share (2024)\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Annexon that uncovers key competitive drivers, buyer and supplier power, entry barriers, substitute threats, and strategic implications for sustaining market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnnexon Porter's Five Forces: a concise one-sheet that maps competitive pressures and therapeutic pipeline threats, letting teams quickly assess supplier\/payer leverage and emerging entrants to inform R\u0026amp;D and partnership decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Programs and Private Insurers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpas annexon moves to commercialization medicare and top private insurers of us drug spend in strong leverage over pricing access.\u003e\u003cpthey set formulary placement and reimbursement often demanding outcomes data real-world cost-effectiveness to grant preferred status.\u003e\u003cpannexon must prove meaningful clinical benefit and favorable cost per qaly often target thresholds secure coverage for neurodegenerative treatments.\u003e\n\u003c\/pannexon\u003e\u003c\/pthey\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs (pharmacy benefit managers) act as gatekeepers, negotiating drug prices for insurers and employers and controlling formulary access; the top three PBMs covered ~80% of US lives in 2024, so Annexon faces concentrated buyer power.\u003c\/p\u003e\n\u003cp\u003ePBMs can demand rebates of 20–50% off list prices for specialty drugs; Annexon’s 2025 revenue outlook will hinge on securing favorable rebate terms versus these few dominant players.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Hospital Networks and Infusion Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBecause Annexon’s lead candidates require infusion, large hospital systems and specialty infusion centers—who accounted for roughly 68% of U.S. infusion drug spend in 2024—are primary purchasers and can steer prescribing and negotiate discounts via volume purchasing and GPOs.\u003c\/p\u003e\n\u003cp\u003eAnnexon must secure formulary placement and pathway integration; if a single hospital chain representing 15–25% of target patients favors alternatives, annual uptake could drop by double digits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partners and Larger Biopharma Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnnexon’s chief customers in the clinical stage are larger biopharma partners seeking licenses or buyouts; their bargaining power is high because they control capital and global commercialization—big deals often set Annexon’s funding runway and milestones. As of 2025 Annexon (NASDAQ: ANNX) had cash ≈$141m at end-2024, so partner terms materially affect valuation and dilution. Major pharma can demand favorable royalty, milestone, or equity terms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical-stage dependence increases buyer leverage\u003c\/li\u003e\n\u003cli\u003eCash ~$141m (YE 2024) makes licensing outcomes vital\u003c\/li\u003e\n\u003cli\u003eValuation tied to deal structure: royalties, milestones, equity\u003c\/li\u003e\n\u003cli\u003eLarge pharmas provide global commercialization and capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups and Consumer Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups in rare disease markets wield outsized influence; 2024 data shows 68% of orphan drug approvals cited patient advocacy input to regulators, so Annexon must factor this into strategy.\u003c\/p\u003e\n\u003cp\u003eThese groups can lobby insurers and public payers, affecting coverage for Annexon’s C1q therapies and prompting price concessions or expanded patient support to preserve access and reputation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% of orphan approvals cite advocacy input (2024)\u003c\/li\u003e\n\u003cli\u003eAdvocacy-led coverage campaigns raised reimbursement for 3 orphan drugs in 2023\u003c\/li\u003e\n\u003cli\u003ePotential pressure to cut list price or expand assistance programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, PBMs \u0026amp; hospitals wield pricing power—rebates 20–50%, access shaped by advocates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppayers top insurers of us drug spend in and pbms three lives hold strong pricing leverage expected rebate demands cut specialty drugs. large hospital systems infusion big pharma partners cash ye further increase buyer power patient advocates orphan approvals cite input can sway coverage access.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003e2024 stat\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e~70% drug spend\u003c\/td\u003e\n\u003ctd\u003eSet access, pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003eTop3 ~80% lives\u003c\/td\u003e\n\u003ctd\u003eRebates 20–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e~68% infusion spend\u003c\/td\u003e\n\u003ctd\u003eNegotiate volume discounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003eCash ≈$141m\u003c\/td\u003e\n\u003ctd\u003eDeal terms affect funding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy\u003c\/td\u003e\n\u003ctd\u003e68% orphan input\u003c\/td\u003e\n\u003ctd\u003eInfluence coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/ppayers\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAnnexon Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Annexon Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders, no mockups, fully formatted and ready for download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747037426041,"sku":"annexonbio-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/annexonbio-five-forces-analysis.png?v=1772194491","url":"https:\/\/matrixbcg.com\/products\/annexonbio-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}